{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:56:35Z","timestamp":1777607795892,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/adm.0000000000000041","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T14:00:56Z","timestamp":1399903256000},"page":"249-257","source":"Crossref","is-referenced-by-count":40,"title":["Hepatitis C Virus\u2013Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance"],"prefix":"10.1097","volume":"8","author":[{"given":"Marija","family":"Zeremski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rositsa B.","family":"Dimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon E.","family":"Zibbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Talal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"12","key":"R1-4-20210126","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/588297","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.","volume":"46","author":"Amon","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"10","key":"R2-4-20210126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"4","key":"R3-4-20210126","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1471-6712.2008.00668.x","article-title":"Increasing public awareness about hepatitis C: development and validation of the brief hepatitis C knowledge scale.","volume":"23","author":"Balfour","year":"2009","journal-title":"Scand J Caring Sci"},{"issue":"2","key":"R4-4-20210126","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10550887.2011.554780","article-title":"Barriers to providing health services for HIVAIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States.","volume":"30","author":"Bini","year":"2011","journal-title":"J Addict Dis"},{"issue":"4","key":"R5-4-20210126","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jsat.2011.09.007","article-title":"Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.","volume":"42","author":"Bini","year":"2012","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"R6-4-20210126","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2005.03.004","article-title":"Knowledge of hepatitis among active drug injectors at a syringe exchange program.","volume":"29","author":"Carey","year":"2005","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"R7-4-20210126","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: an estimate of true prevalence.","volume":"31","author":"Chak","year":"2011","journal-title":"Liver Int"},{"issue":"10","key":"R8-4-20210126","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/jvh.12095","article-title":"Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCVHIV co-infected adults.","volume":"20","author":"Chen","year":"2013","journal-title":"J Viral Hepat"},{"issue":"12","key":"R9-4-20210126","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/10826080902864894","article-title":"Knowledge about hepatitis-C among methadone maintenance treatment patients in Israel.","volume":"45","author":"Cohen-Moreno","year":"2010","journal-title":"Subst Use Misuse"},{"issue":"6","key":"R10-4-20210126","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep.25556","article-title":"Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008.","volume":"55","author":"Denniston","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"R11-4-20210126","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.","volume":"56","author":"Dimova","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"suppl 5","key":"R12-4-20210126","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1086\/427446","article-title":"Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.","volume":"40","author":"Doab","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"R13-4-20210126","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/499960","article-title":"Injection drug users: the overlooked core of the hepatitis C epidemic.","volume":"42","author":"Edlin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"13","key":"R14-4-20210126","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"R15-4-20210126","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","article-title":"Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.","volume":"93","author":"Grebely","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"25","key":"R16-4-20210126","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"R17-4-20210126","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2893.2010.01383.x","article-title":"HIV and HCV health beliefs in an inner-city community.","volume":"18","author":"Krauskopf","year":"2011","journal-title":"J Viral Hepat"},{"issue":"9742","key":"R18-4-20210126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"issue":"9286","key":"R19-4-20210126","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"R20-4-20210126","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2893.2010.01411.x","article-title":"Integrated internistaddiction medicinehepatology model for hepatitis C management for individuals on methadone maintenance.","volume":"19","author":"Martinez","year":"2012","journal-title":"J Viral Hepat"},{"issue":"3","key":"R21-4-20210126","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users.","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"issue":"8","key":"R22-4-20210126","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1525-1497.2005.0161.x","article-title":"Barriers to the treatment of hepatitis C. Patient, provider, and system factors.","volume":"20","author":"Morrill","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"3","key":"R23-4-20210126","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1155\/2011\/810108","article-title":"Physicians attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.","volume":"25","author":"Myles","year":"2011","journal-title":"Can J Gastroenterol"},{"issue":"9791","key":"R24-4-20210126","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"issue":"1-3","key":"R25-4-20210126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2011.10.009","article-title":"Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs.","volume":"123","author":"Park","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"R26-4-20210126","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jurban\/jtg044","article-title":"Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing.","volume":"80","author":"Perlman","year":"2003","journal-title":"J Urban Health"},{"issue":"3","key":"R27-4-20210126","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11524-007-9180-8","article-title":"Offers of hepatitis C care do not lead to treatment.","volume":"84","author":"Schackman","year":"2007","journal-title":"J Urban Health"},{"issue":"8","key":"R28-4-20210126","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cgh.2013.04.024","article-title":"Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review.","volume":"11","author":"Shah","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"R29-4-20210126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0376-8716(00)00144-7","article-title":"Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.","volume":"61","author":"Stein","year":"2001","journal-title":"Drug Alcohol Depend"},{"issue":"suppl 5","key":"R30-4-20210126","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1086\/427445","article-title":"Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users.","volume":"40","author":"Strathdee","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R31-4-20210126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1472-6963-7-39","article-title":"Drug treatment program patients hepatitis C virus (HCV) education needs and their use of available HCV education services.","volume":"7","author":"Strauss","year":"2007","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"R32-4-20210126","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1465-3362.2012.00468.x","article-title":"Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.","volume":"31","author":"Treloar","year":"2012","journal-title":"Drug Alcohol Rev"},{"issue":"4","key":"R33-4-20210126","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment.","volume":"26","author":"Vermehren","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"R34-4-20210126","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jsat.2004.12.004","article-title":"Knowledge of and interest in hepatitis C treatment at a methadone clinic.","volume":"28","author":"Walley","year":"2005","journal-title":"J Subst Abuse Treat"},{"issue":"44","key":"R36-4-20210126","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","article-title":"Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.","volume":"19","author":"Zeremski","year":"2013","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000000041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:56:54Z","timestamp":1620943014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01271255-201407000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000000041","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}